GlassScriptPhysician profile
Leslie L Baker
NPI 1750465001
$1,838.63
in general payments reported to CMS, 2019-2025
22 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $13.66 · 2021: $221 · 2022: $332 · 2023: $403 · 2024: $409 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.29 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $390.94 | 2021-2025 | Nucala |
| Aerin Medical INC. | $307.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $279.49 | 2021-2024 | Dupixent |
| Acclarent, INC | $244.40 | 2023-2024 | Relieva Spinplus, Trudi Nav Cable, Acclarent Navwire |
| Optinose US, INC. | $101.37 | 2019-2024 | |
| Genzyme Corporation | $82.76 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $60.64 | 2022-2023 | Keytruda |
| Stryker Corporation | $56.95 | 2020-2024 | Clarifix Cryotherapy Device |
| Pfizer INC. | $38.73 | 2025 | |
| Intersect Ent, INC. | $36.62 | 2022 | |
| Amgen INC. | $34.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $30.35 | 2021-2022 | |
| Livanova USA, INC. | $28.74 | 2019 | |
| Baxter Healthcare | $22.16 | 2023 | Tisseel |
| Neurent Medical Limited | $20.98 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19.17 | 2024 | Rf20000, Halo, Ent Sinus |
| Sanara Medtech INC. | $18.58 | 2023 | Celleraterx |
| Phadia US INC. | $13.81 | 2019 | |
| Hikma Pharmaceuticals USA | $13.66 | 2024 | Ryaltris |
| Covidien LP | $12.80 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.63 | 2022 | |
| Olympus America INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.